Association of PADI4 single nucleotide polymorphisms with satisfying ACR classification criteria for rheumatoid arthritis by five years, rheumatoid factor (RF) positivity at baseline, and anti-CCP antibody positivity at baseline
| SNP allele | RA by 5 years (%) | Non-RA by 5 years (%) | RF+ at baseline (%) | RF− at baseline (%) | CCP+ at baseline (%) | CCP− at baseline (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *The PADI4 susceptibility haplotype, as defined in the Japanese population, was referred to as 2 and all other haplotypes as 1. | ||||||||||||
| CCP, cyclic citrullinated peptide; RA, rheumatoid arthritis; RF, rheumatoid factor; SNP, single nucleotide polymorphism. | ||||||||||||
| Padi4_89 | ||||||||||||
| G | 370 (59.3) | 129 (60.8) | 124 (59.0) | 373 (60.0) | 44 (56.4) | 216 (65.9) | ||||||
| A | 254 (40.7) | 83 (39.2) | 86 (41.0) | 249 (40.0) | 34 (43.6) | 112 (34.1) | ||||||
| Comparison | p = 0.75 | p = 0.87 | p = 0.15 | |||||||||
| Padi4_90 | ||||||||||||
| T | 354 (58.4) | 120 (58.3) | 116 (58.6) | 355 (58.8) | 45 (56.3) | 203 (63.8) | ||||||
| C | 252 (41.6) | 86 (41.7) | 82 (41.4) | 249 (41.2) | 35 (43.7) | 115 (36.2) | ||||||
| Comparison | p = 1.0 | p = 0.74 | p = 0.25 | |||||||||
| Padi4_92 | ||||||||||||
| G | 348 (55.9) | 116 (56.3) | 116 (56.3) | 347 (56.3) | 42 (55.3) | 201 (61.7) | ||||||
| C | 274 (44.1) | 90 (43.7) | 90 (43.7) | 269 (43.7) | 34 (44.7) | 125 (38.3) | ||||||
| Comparison | p = 0.94 | p = 1.0 | p = 0.36 | |||||||||
| Padi4_104 | ||||||||||||
| T | 425 (67.0) | 148 (70.5) | 133 (63.9) | 435 (68.8) | 50 (62.5) | 234 (72.2) | ||||||
| C | 209 (33.0) | 62 (29.5) | 75 (36.1) | 197 (31.2) | 30 (37.5) | 90 (27.8) | ||||||
| Comparison | p = 0.39 | p = 0.20 | p = 0.10 | |||||||||
| Haplotype* | ||||||||||||
| 1 | 413 (67.0) | 146 (70.9) | 129 (63.9) | 425 (69.0) | 49 (62.8) | 233 (72.4) | ||||||
| 2 | 203 (33.0) | 60 (29.1) | 73 (36.1) | 191 (31.0) | 29 (37.2) | 89 (27.6) | ||||||
| Comparison | p = 0.34 | p = 0.19 | p = 0.10 | |||||||||